PURbridge™, a complicated artificial and new type of bioactive glass, is positioned to considerably enhance the Firm’s income all through 2023
IRVINE, CA – November 23, 2022 /OrthoSpineNews/ – HippoFi, Inc. (previously ORHub), (OTC Pink: ORHB), a diversified firm centered on the biotech and fintech segments, is proud to announce its latest biologic product, PURbridge™. This new type of energetic bioglass expands the already intensive portfolio of HippoFi’s division of Regenerative Therapeutics, which continues to focus on a complete Backbone market, anticipated to achieve $18 billion in 2023.
“Profitable lumbar and thoracic spine fusion surgical procedures require organic merchandise to bridge new bone development between vertebral our bodies. PURbridge™ is uniquely positioned to unravel this crucial affected person want and desired surgical consequence. Our proprietary bridge-like construction has been particularly formulated by interweaving bioactive glass and our absorbent Tri-pore NanoCrystals™ with versatile fibers of semi-crystalline molecules of collagen. This distinctive composition of three extremely biocompatible parts leads to a versatile and robust ‘bioactive bridge’ which holds its form and place whereas serving to the affected person heal, spanning the meant space with stable bone,” defined Ryan Fernan, Head of PUR Biologics.
“Our objective as an rising healthcare chief is to offer progressive biotech merchandise and fintech software program to generate extraordinary development in income, market presence, and innovation,” acknowledged CJ Wiggins, Founder, Govt Chairman & CEO of HippoFi. “PURbridge™ is an excellent medical answer which instantly expands our product portfolio of superior synthetics in Backbone. We’re dedicated to develop into the worldwide chief in organic merchandise for rising bone in spine procedures, to guide the way forward for regenerative therapeutics in regenerating joint cartilage and spinal disc, and to develop into the primary financier and digital fee platform for all surgically implanted merchandise between hospitals, ASC, and medical gadget distributors.”
HippoFi is traded on the OTC underneath the image “ORHB”.
About HippoFi, Inc.
HippoFi, Inc. delivers its cutting-edge healthcare improvements by an in depth gross sales channel community whereas implementing first-to-market options within the multibillion-dollar Biotech, Fintech, and Synthetic Intelligence (AI) markets. HippoFi contains three segments: Regenerative Therapeutics, Digital Funds, and AI, which make the most of the identical buyer channels to commercialize options, drive income, and enhance affected person outcomes.
PUR Biologics®, HippoFi’s Regenerative Therapeutic division, gives a portfolio of progressive organic merchandise and proprietary applied sciences for bone development in surgical Backbone procedures in addition to patented bioactive mobile matrix compositions and superior autologous cell therapies for regenerating cartilage in joints and spinal discs.
HippoFi-Pay™, the corporate’s Digital Fee division, operates a surgical implant and enterprise administration software program, which standardize processes on the level of surgical care with improved logistics and efficiencies to offer medical gadget and biologic distributors with HIPAA & NPI compliant implant verification and sooner funds.
HippoFi’s AI division is concentrated particularly on using AI for early analysis and predictive modeling of Most cancers and enhancing enterprise choices particular to Backbone surgical procedure.
HippoFi, Inc. is publicly traded underneath the image: ORHB and is headquartered in Irvine, California. For extra data, please go to: www.HippoFi.com and www.PURbiologics.com